Mon, Dec 29, 2014, 10:39 AM EST - U.S. Markets close in 5 hrs 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mrkincai mrkincai Feb 20, 2013 7:08 AM Flag

    Seems like consensus on this board is that long term, vascepa succeeds

    And either starts generating $$ from larger market approval, or is bought out. I am expecting the share price to be substantially higher than it is today in one year to two years. Looking at 2015 put option prices, you can collect almost $300 for selling the $8 strike, $415 at $10. And $500 at $12. Even with what we would consider terrible performance in the company, if the share price just makes it to 10 or 12, and remember you have almost a 2 year window, you can collect a lot of cash now, and either use to purchase calls, or just lower your average price on the stock. Just curious if anyone else is looking at selling these inflated options out to2015. The risk seems limited because we have an actual drug on the shelf.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think it is a really stupid play frankly. This company will either be $18-$25 in two years of $2 on it's way to zero. You get the taxable premium right now and you spend it. Then in two years someone puts it to you at
      $8 and the stock is $3 and you don't even remember doing the stupid strategy that got you into the mess...LOL! Stay away from optioins on this one. Much too uncertain. Much too volatile. The risk is limited,,,
      To $8.67 on the downside if GIA fails...IMHO!

    • these 4 sitting bottom , ready for takeoff: AMRN, ARNA, NVIV, VRNG

      Sentiment: Strong Buy

 
AMRN
0.985-0.015(-1.50%)10:37 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.